Repare Therapeutics is a cancer research company located in Canada and the United States. They use their SNIPRx platform to develop targeted therapies that focus on genomic instability and DNA damage repair. Their lead product RP-3500 is a small molecule inhibitor for solid tumors with specific DNA damage repair genetic alterations.